Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av BBT001 hos friska frivilliga (HV) och hos vuxna patienter med atopisk dermatit (AD)

26 september 2026 uppdaterad av: Bambusa Therapeutics

En randomiserad, blindad, placebokontrollerad, enkel- och multipelhärdad dosstudie för att utvärdera säkerhet, tolerabilitet, farmakokinetik, immunogenicitet, farmakodynamik och klinisk aktivitet av BBT001 hos HV: er och AD-patienter

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.

Studietyp

Interventionell

Inskrivning (Beräknad)

237

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Western Australia
      • Fremantle, Western Australia, Australien, 6160
        • Rekrytering
        • Fremantle Dermatology
      • Perth, Western Australia, Australien, 6009
        • Avslutad
        • Linear Clinical Research
    • California
      • Irvine, California, Förenta staterna, 92614
        • Rekrytering
        • First OC Dermatology
    • New York
      • New York, New York, Förenta staterna, 10128
        • Rekrytering
        • OptiSkin Medical
      • The Bronx, New York, Förenta staterna, 10455
        • Rekrytering
        • Equity Medical, LLC
      • Christchurch, Nya Zeeland
        • Rekrytering
        • Optimal Clinical Trials Ltd - Christchurch
      • Upper Hutt, Nya Zeeland, 5018
        • Rekrytering
        • Pacific Clinical Research Network (PCRN) Wellington
        • Kontakt:
          • Tim Humphrey
    • Auckland
      • Grafton, Auckland, Nya Zeeland, 1010
        • Rekrytering
        • Optimal Clinical Trials Central Auckland
        • Kontakt:
          • Arna Letica
      • Otahuhu, Auckland, Nya Zeeland, 2025
        • Indragen
        • Aotearoa Clinical Trials
      • Takapuna, Auckland, Nya Zeeland, 0622
        • Rekrytering
        • Pacific Clinical Research Network (PCRN) - Auckland
        • Kontakt:
          • Paul Hamilton
      • Lodz, Polen, 91-347
        • Rekrytering
        • Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
      • Rzeszów, Polen, 35-055
        • Rekrytering
        • Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
      • Warsaw, Polen, 02-507
        • Rekrytering
        • Państwowy Instytut Medyczny MSWiA
      • Wroclaw, Polen, 50-566
        • Rekrytering
        • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 72 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria

  1. Negative pregnancy tests for women of childbearing potential.
  2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
  3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
  4. Adequate contraception use (for men and women of childbearing potential).

Key Inclusion Criteria (Parts A, B, and D)

  1. Age of 18-65 years.
  2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
  3. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Parts C and E only)

  1. Age of 18-72 years.
  2. Body mass index ≥16 kg/m², weight capped at 125 kg.
  3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
  4. Moderate to severe atopic dermatitis
  5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
  6. Atopic lesions cover ≥10% of body surface area (BSA)
  7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Key Exclusion Criteria

  1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
  2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
  3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
  4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
  5. Abnormal Electrocardiogram (ECG) findings
  6. History of drug/alcohol abuse in the past 2 years.
  7. Donated >500mL blood within 2 months of screening.
  8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria (Parts A, B, and D only)

1. History of atopic dermatitis

Key Exclusion Criteria (Parts C and E only)

  1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
  2. Receipt of immunoglobulin or blood products within 30 days.
  3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
  4. Chronic pruritus from conditions other than atopic dermatitis.
  5. Acute/treated infections or chronic skin infections.
  6. Current use of sedating antihistamines or corticosteroids.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part A Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Experimentell: Part B Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in healthy volunteers.

BBT001 will be administered

Experimentell: Part C Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo-jämförare: Part A Single Ascending Dose Placebo

A single dose of Placebo will be administered in healthy volunteers

Placebo will be administered

Placebo-jämförare: Part B Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in healthy volunteers.

Placebo will be administered

Placebo-jämförare: Part C Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Aktiv komparator: Part D Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

BBT001 will be administered

Placebo-jämförare: Part D Single Ascending Dose Placebo

A single dose of placebo will be administered in healthy volunteers

Placebo will be administered

Aktiv komparator: Part E Multiple Ascending Dose BBT001 - Dose Level 1

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

BBT001 will be administered

Placebo-jämförare: Part E Multiple Ascending Dose Placebo

Multiple doses of placebo will be administered in patients with atopic dermatitis.

Placebo will be administered

Aktiv komparator: Part E Multiple Ascending Dose BBT001 - Dose Level 2

Multiple doses of BBT001 will be administered in patients with atopic dermatitis

BBT001 will be administered

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of participants with adverse events following single and multiple administration of BBT001
Tidsram: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in serum blood parameters
Tidsram: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Laboratory assessments include hematology, blood chemistry and coagulation test

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in vital sign measurements following treatment administration.
Tidsram: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Blood pressure and heart rate will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in physical examination following treatment administration.
Tidsram: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Physical examination will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
Number of participants with change in 12-lead ECG readings
Tidsram: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

12-lead ECG will be assessed.

Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
Tidsram: At specified timepoints pre-dose and up to 169 days post first dose administration

Maximum observed concentration of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
Tidsram: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum PK Tmax will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Area under the curve (AUC)
Tidsram: At specified timepoints pre-dose and up to 169 days post first dose administration

Area under the curve of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Volume of distribution (Vz)
Tidsram: At specified timepoints pre-dose and up to 169 days post first dose administration

Volume of distribution of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Total clearance (CL)
Tidsram: At specified timepoints pre-dose and up to 169 days post first dose administration

Total clearance of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
Pharmacokinetics parameters - Elimination Half-life (t1/2).
Tidsram: At specified timepoints pre-dose and up to 169 days post first dose administration

Elimination half-life of the study drug in serum will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
Tidsram: At specified timepoints pre-dose and up to 169 days post first dose administration

Serum Anti-Drug Antibodies will be analyzed for all subjects

At specified timepoints pre-dose and up to 169 days post first dose administration

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Lisa Li, Bambusa Therapeutics, Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

27 februari 2025

Primärt slutförande (Beräknad)

28 februari 2027

Avslutad studie (Beräknad)

28 februari 2027

Studieregistreringsdatum

Först inskickad

30 januari 2025

Först inskickad som uppfyllde QC-kriterierna

30 januari 2025

Första postat (Faktisk)

5 februari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

26 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera